Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: SURPASS-CVOT
Nissen SE, Wolski K, D'Alessio D, Weerakkody G, Kiljanski J, Wiese RJ, Pavo I, Cariou B, Nicholls SJ
Summary
In a post hoc analysis of the landmark SURPASS-CVOT trial (n=13,165), tirzepatide demonstrated a 16% relative risk reduction in a composite 6-component cardiorenal endpoint compared to dulaglutide (HR 0.84, 95% CI 0.79-0.90, p<0.001). The benefit extended across all-cause mortality, MI, stroke, coronary revascularization, heart failure hospitalization, and adverse kidney outcomes over a median 47-month follow-up.
Clinical Significance
This is the first head-to-head comparison showing dual GIP/GLP-1 agonism (tirzepatide) provides superior cardiorenal protection versus GLP-1 agonism alone (dulaglutide) in patients with established CVD. The findings strengthen the case for tirzepatide as a preferred incretin-based therapy in high-risk patients and may influence treatment guidelines for cardiometabolic risk reduction.
Pesquisa Relacionada
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: TOGETHER-PsA Trial
In the TOGETHER-PsA trial (n=271), combining tirzepatide with ixekizumab achieved ACR50 + ≥10% weigh…
Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide
This real-world study of 293 patients found that tirzepatide produced 10.3% total body weight loss i…
Glucagon-like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis examined the relationship between GLP-1 receptor agonist use and de…
Tirzepatide/Semaglutide Weight Loss Intervention in Patients With Endometrial Cancer and Obesity
Memorial Sloan Kettering is conducting a pilot study evaluating tirzepatide (with semaglutide as alt…